cilostamide has been researched along with Diabetes Mellitus, Type 2 in 1 studies
cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Netherton, SJ | 1 |
| Jimmo, SL | 1 |
| Palmer, D | 1 |
| Tilley, DG | 1 |
| Dunkerley, HA | 1 |
| Raymond, DR | 1 |
| Russell, JC | 1 |
| Absher, PM | 1 |
| Sage, EH | 1 |
| Vernon, RB | 1 |
| Maurice, DH | 1 |
1 other study available for cilostamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imi | 2002 |